Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New treatments for metastatic melanoma.

Literature DB >> 24549129

New treatments for metastatic melanoma.

Craig Gedye¹, David Hogg¹, Marcus Butler¹, Anthony M Joshua².

Abstract

Entities: Disease

Mesh：

Year: 2014 PMID： 24549129 PMCID： PMC4081198 DOI： 10.1503/cmaj.130989

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

× No keyword cloud information.

33 in total

1. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

Authors: Mark E Dudley; James C Yang; Richard Sherry; Marybeth S Hughes; Richard Royal; Udai Kammula; Paul F Robbins; JianPing Huang; Deborah E Citrin; Susan F Leitman; John Wunderlich; Nicholas P Restifo; Armen Thomasian; Stephanie G Downey; Franz O Smith; Jacob Klapper; Kathleen Morton; Carolyn Laurencot; Donald E White; Steven A Rosenberg
Journal: J Clin Oncol Date: 2008-09-22 Impact factor: 44.544

2. Distinct sets of genetic alterations in melanoma.

Authors: John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245

3. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors: Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal: Clin Cancer Res Date: 2009-11-24 Impact factor: 12.531

Review 4. Immunotherapy of advanced or metastatic melanoma.

Authors: Jonathan Cebon; Craig Gedye; Thomas John; Ian D Davis
Journal: Clin Adv Hematol Oncol Date: 2007-12

5. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.

Authors: David R Minor; Kevin Chin; Mohammed Kashani-Sabet
Journal: Cancer Biother Radiopharm Date: 2009-06 Impact factor: 3.099

6. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors: Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal: Nat Med Date: 2002-06-24 Impact factor: 53.440

7. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.

Authors: Michal J Besser; Ronnie Shapira-Frommer; Orit Itzhaki; Avraham J Treves; Douglas B Zippel; Daphna Levy; Adva Kubi; Noa Shoshani; Dragoslav Zikich; Yaara Ohayon; Daniel Ohayon; Bruria Shalmon; Gal Markel; Ronit Yerushalmi; Sara Apter; Alon Ben-Nun; Eytan Ben-Ami; Avichai Shimoni; Arnon Nagler; Jacob Schachter
Journal: Clin Cancer Res Date: 2013-05-20 Impact factor: 12.531

8. Prognostic factors in 1,521 melanoma patients with distant metastases.

Authors: A Barth; L A Wanek; D L Morton
Journal: J Am Coll Surg Date: 1995-09 Impact factor: 6.113

9. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells.

Authors: G M Halliday; A Patel; M J Hunt; F J Tefany; R S Barnetson
Journal: World J Surg Date: 1995 May-Jun Impact factor: 3.352

10. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.

Authors: Bijay S Jaiswal; Vasantharajan Janakiraman; Noelyn M Kljavin; Jeffrey Eastham-Anderson; James E Cupp; Yuxin Liang; David P Davis; Klaus P Hoeflich; Somasekar Seshagiri
Journal: PLoS One Date: 2009-05-27 Impact factor: 3.240

4 in total